[Questionable efficacy and safety of activated drotrecogin alpha (activated protein C) in the treatment of severe sepsis]

Ned Tijdschr Geneeskd. 2006 Jun 3;150(22):1265-6; author reply 1266.
[Article in Dutch]
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Anti-Infective Agents / adverse effects
  • Anti-Infective Agents / therapeutic use*
  • Consumer Product Safety*
  • Humans
  • Practice Guidelines as Topic
  • Protein C / adverse effects*
  • Protein C / therapeutic use*
  • Recombinant Proteins / adverse effects
  • Recombinant Proteins / therapeutic use
  • Sepsis / drug therapy*
  • Sepsis / mortality
  • Treatment Outcome

Substances

  • Anti-Infective Agents
  • Protein C
  • Recombinant Proteins
  • drotrecogin alfa activated